The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Abbvie Inc shares valued at $2,639,966 were purchased by NICHOLAS DONOGHOE on Aug 05 ’25. At $198.51 per share, NICHOLAS DONOGHOE acquired 13,299 shares.
Also, Stewart Jeffrey Ryan sold 58,832 shares, netting a total of over 12,359,504 in proceeds. Following the sale of shares at $210.08 each, the insider now holds 53,234 shares.
Before that, Stewart Jeffrey Ryan had added 58,832 shares to its account. In a trade valued at $12,359,897, the Officer bought Abbvie Inc shares for $210.09 each.
As published in a research note from Citigroup on May 14, 2025, Abbvie Inc [ABBV] has been rated down from a Buy to a Neutral and the price target has been revised to $205. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. Earlier on December 05, 2024, Daiwa Securities downgraded its rating. Their new recommendation was “a Neutral” for ABBV stock which previously was a “an Outperform”.
Analyzing ABBV Stock Performance
On last trading session, Abbvie Inc [NYSE: ABBV] plunged -1.13% to $196.3. The stock’s lowest price that day was $194.67, but it reached a high of $198.05 in the same session. During the last five days, there has been a surge of approximately 3.69%. Over the course of the year, Abbvie Inc shares have jumped approximately 3.70%.
Is Abbvie Inc subject to short interest?
Stocks of Abbvie Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.91 million shares to 15.61 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 14.7 million shares. A jump of 5.82% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.23 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.23.
Which companies own the most shares of Abbvie Inc (ABBV)?
In terms of Abbvie Inc share price expectations, FactSet research, analysts set an average price target of 172 in the next 12 months, down nearly -13.37% from the previous closing price of $198.55. Analysts anticipate Abbvie Inc stock to reach 226 by 2025, with the lowest price target being 127. In spite of this, 27 analysts ranked Abbvie Inc stock as Buy at the end of 2025. On November 22, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and upgraded coverage with a $206.
